- Tarsus to Participate in Upcoming Investor Conferences
- Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference
- Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements
- Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
- Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
- Tarsus to Participate at Upcoming Investor Conferences
- Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
- Tarsus Announces Pricing of $100.0 Million Public Offering
- Tarsus Announces Proposed $100.0 Million Public Offering
- Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
More ▼
Key statistics
As of last trade Tarsus Pharmaceuticals Inc (TARS:NSQ) traded at 32.65, -23.19% below its 52-week high of 42.50, set on May 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 32.65 |
---|---|
High | 33.07 |
Low | 31.63 |
Bid | 32.60 |
Offer | 32.68 |
Previous close | 32.63 |
Average volume | 414.47k |
---|---|
Shares outstanding | 37.78m |
Free float | 33.21m |
P/E (TTM) | -- |
Market cap | 1.25bn USD |
EPS (TTM) | -4.72 USD |
Data delayed at least 15 minutes, as of Jun 04 2024 19:49 BST.
More ▼